Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Lynch

Showing results (21-30 of 251) with videos related to

Pageof 26
Sort By:
Expert Review of Neurotherapeutics|January 25, 2024
Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerationsDavid R Lynch, Susan Perlman, Kim Schadt
Movement Disorders : Official Journal of the Movement Disorder Society|January 11, 2019
Etravirine in Friedreich's ataxia: Lessons from HIV?David R Lynch, Kimberly Schadt, Elizabeth Kichula
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 7, 2018
Frataxin Restoration in the Nervous System: Possibilities for Gene TherapyDavid R Lynch, Elizabeth Kichula, Hong Lin
Archives of Neurology|August 11, 2010
A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxiaDavid R Lynch, Susan L Perlman, Thomas Meier
Brain : a Journal of Neurology|July 29, 2024
Autoimmune 'secondary synaptopathies': do NMDAR antibodies cause a primary extra-synaptopathy?Meng Zhao, David R Lynch, Sarosh R Irani
Neurodegenerative Disease Management|January 15, 2025
Friedreich ataxia: what can we learn from non-GAA repeat mutations?David R Lynch, M Shen, Robert B Wilson
Annals of Clinical and Translational Neurology|November 26, 2025
Domain Specific Placebo Response in the Modified Friedreich's Ataxia Rating ScaleChristian Rummey, Jennifer M Farmer, David R Lynch
American Journal of Medical Genetics. Part A|June 27, 2007
Ovarian failure in ataxia with oculomotor apraxia type 2David R Lynch, Corey D Braastad, Narasimhan Nagan
Eclinicalmedicine|January 16, 2020
Predictors of loss of ambulation in Friedreich's ataxiaChristian Rummey, Jennifer M Farmer, David R Lynch
Annals of Clinical and Translational Neurology|February 24, 2024
Phenotypic variation of FXN compound heterozygotes in a Friedreich ataxia cohortMegan M Shen, Christian Rummey, David R Lynch
Pageof 26

Showing results (21-30 of 251) with videos related to

Sort By:
Pageof 26
Expert Review of Neurotherapeutics|January 25, 2024
Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerationsDavid R Lynch, Susan Perlman, Kim Schadt
Movement Disorders : Official Journal of the Movement Disorder Society|January 11, 2019
Etravirine in Friedreich's ataxia: Lessons from HIV?David R Lynch, Kimberly Schadt, Elizabeth Kichula
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 7, 2018
Frataxin Restoration in the Nervous System: Possibilities for Gene TherapyDavid R Lynch, Elizabeth Kichula, Hong Lin
Archives of Neurology|August 11, 2010
A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxiaDavid R Lynch, Susan L Perlman, Thomas Meier
Brain : a Journal of Neurology|July 29, 2024
Autoimmune 'secondary synaptopathies': do NMDAR antibodies cause a primary extra-synaptopathy?Meng Zhao, David R Lynch, Sarosh R Irani
Neurodegenerative Disease Management|January 15, 2025
Friedreich ataxia: what can we learn from non-GAA repeat mutations?David R Lynch, M Shen, Robert B Wilson
Annals of Clinical and Translational Neurology|November 26, 2025
Domain Specific Placebo Response in the Modified Friedreich's Ataxia Rating ScaleChristian Rummey, Jennifer M Farmer, David R Lynch
American Journal of Medical Genetics. Part A|June 27, 2007
Ovarian failure in ataxia with oculomotor apraxia type 2David R Lynch, Corey D Braastad, Narasimhan Nagan
Eclinicalmedicine|January 16, 2020
Predictors of loss of ambulation in Friedreich's ataxiaChristian Rummey, Jennifer M Farmer, David R Lynch
Annals of Clinical and Translational Neurology|February 24, 2024
Phenotypic variation of FXN compound heterozygotes in a Friedreich ataxia cohortMegan M Shen, Christian Rummey, David R Lynch
Pageof 26